Quercetin enhances the effects of 5-fluorouracil-mediated growth inhibition and apoptosis of esophageal cancer cells by inhibiting NF-κB

Oncology Letters

Volumn 4, Issue 4, 2012, Pages 775-778

  Chuang Xin, Lu ^a   Wen Yu, Wang ^a   Yao, Cui ^a   Xiao Yan, Li ^a   Yun, Zhou ^a  

^a HENAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

5 fluorouracil; Esophageal cancer; NF B; Quercetin

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; FLUORESCEIN ISOTHIOCYANATE; FLUOROURACIL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOCORTIN 5; PROPIDIUM IODIDE; QUERCETIN;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL ASSAY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; ESOPHAGUS CANCER; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; STATISTICAL SIGNIFICANCE; WESTERN BLOTTING;

EID: 84864695680     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.829     Document Type: Article

References (27)

1. Greenlee RT, Murray T, Bolden S and Wingo PA: Cancer Statistics. CA Cancer J Clin 50: 7-33, 2000.
2. Li J, Minnich DJ, Camp ER, Brank A, Mackay SL and Hochwald SN: Enhanced sensitivity to chemotherapy in esophageal cancer through inhibition of NF-κB. J Surg Res 132: 112-120, 2006.
3. Lee CT, Seol JY, Lee SY, et al: The effect of adenovirus-Ikappa Balpha transduction on the chemosensitivity of lung cancer cell line with resistance to cis-diaminedichloroplatinum (II) (cisplatin) and doxorubicin (adriamycin). Lung Cancer 41: 199-206, 2003.
4. Shim HJ, Cho SH, Hwang JE, et al: Phase II study of docetaxel and cisplatin chemotherapy in 5-fluorouracil/cisplatin pretreated esophageal cancer. Am J Clin Oncol 33: 624-628, 2010.
5. Friesen C, Herr I, Krammer PH and Debatin KM: Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med 2: 574-577, 1996.
6. Fulda S, Susin SA, Kroemer G and Debatin KM: Molecular ordering of apoptosis induced by anticancer drugs in neuroblastoma cells. Cancer Res 58: 4453-4460, 1998.
7. Fisher DE: Apoptosis in cancer therapy: crossing the threshold. Cell 78: 539-542, 1994.
8. Lotem J and Sachs L: Regulation by bcl-2, c-myc, and p53 of susceptibility to induction of apoptosis by heat shock and cancer chemotherapy compounds in differentiation-competent and -defective myeloid leukemic cells. Cell Growth Differ 4: 41-47, 1993.
9. Wang CY, Mayo MW, Korneluk RG, Goeddel DV and Baldwin AS Jr: NF-κB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 281: 1680-1683, 1998.
10. Wang CY, Mayo MW and Baldwin AS Jr: TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κB. Science 274: 784-787, 1996.
11. Voboril R, Hochwald SN, Li J, Brank A, Weberova J, Wessels F, Moldawer LL, Camp ER and MacKay SL: Inhibition of NF-kappa B augments sensitivity to 5-fluorouracil/folinic acid in colon cancer. J Surg Res 120: 178-188, 2004.
12. Cusack JC Jr, Liu R, Houston M, et al: Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-κB inhibition. Cancer Res 61: 3535-3540, 2001.
13. Hertog MG, Hollman PC, Katan MB and Kromhout D: Intake of potentially anticarcinogenic flavonoids and their determinants in adults in the Netherlands. Nutr Cancer 20: 21-29, 1993.
14. Csokay B, Prajda N, Weber G and Olah E: Molecular mechanisms in the antiprolife- rative action of quercetin. Life Sci 60: 2157-2163, 1997.
15. Casagrande F and Darbon JM: Effects of structurally related flavonoids on cell cycle progression of human melanoma cells: regulation of cyclin-dependent kinases CDK2 and CDK1. Biochem Pharmacol 61: 1205-1215, 2001.
16. Nguyen TT, Tran E, Nguyen TH, Do PT, Huynh TH and Huynh H: The role of activated MEK-ERK pathway in quercetin-induced growth inhibition and apoptosis in A549 lung cancer cells. Carcinogenesis 25: 647-659, 2004.
17. Kawada K, Yonei T, Ueoka H, et al: Comparison of chemosensitivity tests: clonogenic assay versus MTT assay. Acta Med Okayama 56: 129-134, 2002.
18. Lam MH, Liu Q, Elledge SJ and Rosen JM: Chk1 is haploinsufficient for multiple functions critical to tumor suppression. Cancer Cell 6: 45-59, 2004.
19. Yamamura Y, Lee WL, Goh MX and Ito Y: Role of TAp73alpha in induction of apoptosis by transforming growth factor-beta in gastric cancer cells. FEBS Lett 582: 2663-2667, 2008.
20. Kurokawa M, Zhao C, Reya T and Kornbluth S: Inhibition of apoptosome formation by suppression of Hsp90beta phosphorylation in tyrosine kinase-induced leukemias. Mol Cell Biol 28: 5494-5506, 2008.
21. Hanahan D and Weinberg RA: The hallmarks of cancer. Cell 100: 57-70, 2000.
22. Zimmermann KC and Green DR: How cells die: apoptosis pathways. J Allergy Clin Immunol 108 (Suppl 4): 99-103, 2001.
23. Chen F, Beezhold K and Castranova V: Tumor promoting or tumor suppressing of NF-kappa B, a matter of cell context dependency. Int Rev Immunol 27: 183-204, 2008.
24. Jobin C, Panja A, Hellerbrand C, et al: Inhibition of proinflammatory molecule production by adenovirus-mediated expression of a nuclear factor kappaB super-repressor in human intestinal epithelial cells. J Immunol 160: 410-418, 1998.
25. Hinz M, Loser P, Mathas S, Krappmann D, Dorken B and Scheidereit C: Constitutive NF-kappaB maintains high expression of a characteristic gene network, including CD40, CD86, and a set of antiapoptotic genes in Hodgkin/Reed-Sternberg cells, Blood 97: 2798-2807, 2001.
26. Huang S, Pettaway CA, Uehara H, Bucana CD and Fidler IJ: Blockade of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene 20: 4188-4197, 2001.
27. Bian X, Opipari AW Jr, Ratanaproeksa AB, et al: Constitutively active NFkappa B is required for the survival of S-type neuroblastoma. J Biol Chem 277: 42144-42150, 2002.